In the News

PPD is expanding its operations and leadership team in China to provide enhanced clinical development, laboratory, regulatory, site conduct, patient access and post-approval services for international and China-based biopharmaceutical companies.

The initial public offering price is expected to be between $24.00 and $27.00 per share.

PPD has applied to have its common stock approved for listing on The Nasdaq Global Select Market under the symbol “PPD.”

There is no question that clinical trial management is becoming more complex. Instead of engaging with patients, an inordinate amount of time is spent learning new systems, completing redundant required training and reentering the same data multiple times.

Tim King and Brian Ford discuss the concept of moving capacity management from sponsors to their FSP vendors.

PPD adds clinical research unit with ‘strong’ recruiting track record to its portfolio, enabling studies on patient populations ‘more reflective’ of the products’ end-users.

Dawie Wessels of AES comments on the cause and treatment of non-alcoholic steatohepatitis (NASH).

A shortage of high-quality sites are available for sponsors for certain indications and parts of the world. PPD recognized this obstacle and sought out to address this need.

How democratization of data is powering a new wave of opportunities.